Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal microplasmin dose-escalation before vitrectomy for vitreomacular traction maculopathy
2005-001171-36Phase 2Completed
- Sponsor
- Oxurion
- Start
- Jun 2005
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ocriplasmin in vitreomacular traction (VMT), sponsored by Oxurion. Primary endpoints: Safety and Preliminary efficacy. Started Jun 2005; status: completed.
02
Drugs
ocriplasmin
03
Conditions
vitreomacular traction (VMT)
Beyond the preview
Go deeper on 2005-001171-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001171-36.